Latest Breaking News On - Sheldon koenig - Page 1 : comparemela.com

Daiichi Sankyo Europe GmbH: First-in-class cholesterol-lowering treatment NILEMDO? and its combination with ezetimibe, NUSTENDI?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk

NILEMDO? (bempedoic acid), a first-in-class, oral treatment and NUSTENDI? (bempedoic acid ezetimibe fixed-dose combination) receive label update approval from the European Commission as treatments

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

Esperion Reports First Quarter 2024 Financial Results

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents.

What's Going On With Esperion Therapeutics Stock On Tuesday? - Esperion Therapeutics (NASDAQ:ESPR)

FDA Approval Broadens Eligibility for Treatment With Nexletol, Nexlizet

The FDA has expanded the approval of Nexletol and Nexlizet to prevent myocardial infarction and coronary revascularization in both primary and secondary prevention patients.